EX-99.1

2 ea030215301ex99-1.htm

PRESS RELEASE ISSUED ON AUGUST 17, 2026

Exhibit 99.1

20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level

Total Revenue Increased 37% to $0.7 Million and Gross Profit Increased 87% to $0.3 Million, with Gross Margin Expanding to 41.7% from 30.5%

Best Quarter of Multi-Cancer

Early Detection Testing, with OneTest™ Revenue Up 47% Year-Over-Year to $0.7 Million

Cash Position Strengthened to $4.5 Million as of June 30, 2026, with All Convertible Note Debt Eliminated During the Quarter

Gaithersburg, MD - August 17, 2026 - 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported its financial and operational results for the second quarter ended June 30, 2026.

Second Quarter & Subsequent 2026 Operational Highlights

●Total revenue increased 36.5% to $0.7 million for Q2 2026, as compared to $0.5 million for Q2 2025, with OneTest™ accounting for 95.3% of total revenue in the quarter, up from 88.4% in the prior year period.

●Revenue from the Company’s OneTest™ family of blood tests, led by OneTest™ for Cancer, its Multi-Cancer Early Detection (“MCED”) blood test, increased 47.1% to $0.7 million for Q2 2026, as compared to $0.5 million for Q2 2025. The Company believes Q2 2026 represented its strongest quarter of MCED testing.

●Gross profit increased 86.6% to $0.3 million for Q2 2026, as compared to $0.2 million for Q2 2025, while gross margin expanded to 41.7% from 30.5%, reflecting improved absorption of fixed laboratory costs across a higher volume of OneTest™ tests.

●State-funded firefighter cancer screening programs continued to gain momentum. In May, the State of Vermont selected OneTest™ for a 12-month statewide initiative to screen up to 4,500 firefighters, while Maryland fire departments were awarded $520,000 for OneTest™ cancer screenings. The Company expects these programs to generate more than $1.0 million of revenue through the end of 2026.

●The Company expects to have tested more than 35,000 firefighters by the end of 2026, building a body of real-world evidence intended to support its regulatory and reimbursement strategy.

●Received orders from 29 new accounts during the second quarter, including occupational and preventive health companies, fire departments and primary care physician practices. Growth has continued into the third quarter across fire department, occupational health, military service and physician practice markets.

●Executed a purchase agreement with the TF – 7294 Foundation that expands access to OneTest™ for Cancer within the U.S. Intelligence Community.

●Received a first commercial order from BodyMetRX, extending the OneTest™ for Cancer footprint into the health optimization and wellness market.

●Maintained strong repeat business from existing customers, with Clayton County, Georgia beginning its seventh year of OneTest™ for Cancer screening, and continued to grow its enterprise pipeline entering the second half of 2026.

●Launched a three-month retail pilot with Giant Food for OneTest for Longevity™, making the Company’s inflammatory and cardiometabolic biomarker testing available through participating Giant Food stores via pharmacy-based blood collection and at-home self-collection kits.

●Cash and cash equivalents totaled $4.5 million as of June 30, 2026, compared to $1.0 million as of December 31, 2025.

●Issued an additional 1,000 shares of Series E convertible preferred stock on June 16, 2026 for gross proceeds of $1.0 million, bringing total Series E proceeds to $6.0 million for the first half of 2026 under a preferred purchase agreement pursuant to which up to $40.0 million in capital may be raised in multiple tranches, subject to 20/20 meeting certain conditions.

●Subsequent to the first quarter, on April 10, 2026, all principal and accrued interest outstanding under the Company’s secured convertible promissory notes was exchanged for 583 shares of Series E convertible preferred stock, eliminating all convertible note debt from the Company’s balance sheet as of June 30, 2026.

●Subsequent to quarter end, on July 16, 2026, the Company entered into a standstill agreement with Streeterville under which Streeterville agreed that, for 120 days, it will not convert shares of Series E convertible preferred stock into common stock unless the common stock trades at least 10% above the “Minimum Price” as defined in Nasdaq Rule 5635.

●Accounts receivable increased to approximately $0.3 million as of June 30, 2026, compared to $0.2 million as of December 31, 2025, reflecting higher MCED testing volume late in the quarter.

●Hosted the inaugural session of a new monthly investor webinar series on July 1, 2026, focused on the Company’s Medicare strategy for OneTest™ and its serial biomarker tracking

EX-99.1

2 ea028443201ex99-1.htm

PRESS RELEASE ISSUED ON MARCH 31, 2026

Exhibit 99.1

20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress

Full Year 2025 Revenue of $2.0 Million, up 17% from 2024

Gross Profit Increased 68% in FY 2025 and Gross Margin Expanded 900 bps

State-Funded Firefighter Cancer Screening Program

Expected to Drive Significant Revenue Growth in Q2 and Full Year 2026

Recent Nasdaq Listing Under Ticker Symbol “AIDX” and New Growth Initiatives Position 20/20 BioLabs for 2026 Expansion

Gaithersburg, MD — March 31, 2026 — 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today reported its financial and operational results for the full year ended December 31, 2025.

Fourth Quarter & Subsequent 2026 Operational Highlights

●Revenue of $2.0 million for FY 2025, representing an increase of 17% over FY 2024.

●Deferred revenue totaled approximately $0.4 million as of December 31, 2025.

●Gross profit of $0.6 million for FY 2025, representing an increase of 68% over FY 2024. Gross margin was 29.6% in FY 2025, compared to 20.6% in FY 2024.

●Total operating expenses decreased 35% to $3.9 million in FY 2025 compared to $6.0 million in FY 2024.

●FY 2025 net loss improved 33% to ($3.7) million, compared to ($5.6) million in FY 2024.

●Net cash used in operating activities decreased to $1.9 million for FY 2025, compared to $2.6 million in FY 2024.

●Cash balance was $1.0 million as of December 31, 2025.

●Completed a $5.0 million private placement on February 19, 2026 under a preferred purchase agreement pursuant to which up to $40 million in capital may be raised in multiple tranches, subject to 20/20 Biolabs meeting certain conditions.

●$520,000 in funding from the Maryland Department of Health (MDH) for cancer screenings using OneTest ™ Multi-Cancer Early Detection (MCED) blood test awarded to 18 Maryland fire departments.

●Entered into an exclusive U.S. license agreement with ROKIT Healthcare to integrate advanced CKD prediction technology into its Longevity Test Program.

●Launched OneTest™ for Longevity blood test and chronic disease risk assessment and management solution built with IBM¹ AI capabilities.

●Provided an update on its patented protein tumor marker (PTM) based, machine learning (ML) derived multi-cancer early detection (MCED) methodology in the wake of several recent studies suggesting the expected value of this approach for earlier stage detection compared to stand-alone circulating tumor DNA (ctDNA) based MCEDs.

¹IBM is acting as an information technology provider only. IBM does not purport to be engaged in the practice of medicine or any other professional clinical or licensed activity. IBM’s offerings are not designed or intended to constitute protocols for delivering medical care; a substitute for professional medical advice, diagnosis, treatment or judgment; a drug, drug-adjunct technology, or drug development tool subject to quality system requirements; or medical device as defined under the laws of any jurisdiction.

●The Medicare Multi-Cancer Early Detection Screening Act was signed into law on February 3, 2026, creating a pathway for Medicare reimbursement for MCEDs by 2028

●Commenced trading on the Nasdaq Capital Market under the ticker symbol “AIDX” on February 19, 2026.

Management Commentary

“The fourth quarter and full year 2025 delivered strong revenue growth, expanded gross margins, and lowered costs as we continued to build on our innovative product portfolio with the launch of OneTest™ for Longevity,” said Jonathan Cohen, Chief Executive Officer of 20/20 BioLabs. “Revenue was $2.0 million in the full year 2025, up 17% year over year, further validating our strategy to provide early detection that saves lives in the fast-growing Multi-Cancer Early Detection (MCED) market. Gross margin expanded 900 basis points to 29.6% in 2025, and operating expenses decreased 35% to $3.9 million, providing a line of sight toward profitability. We also reduced net cash used in operating activities to $1.9 million, reflecting the operating discipline we believe will be important as we scale the business. Combined with our recent listing on the Nasdaq and PIPE financing, we believe we are well positioned for substantial growth going forward.”

“Growth has been fueled primarily by our OneTest™ MCED blood test, which has been demonstrated to identify many cancer types at earlier stages than competing ctDNA based MCEDs in a large and growing market focused on earlier cancer detection. Most recently, 18 Maryland fire departments have been notified that they will collectively be awarded over $520,000 from the Maryland Department of Health to procure and administer OneTest™ MCED blood tests, representing an increase of approximately 225% in the number of OneTest MCEDs funded through the same progr